海外の治験の状況「1」での検索結果
544件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
- Crohn Disease
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Finland, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-03-12
Recruiting
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- Crohn's Disease
- Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Korea, Republic of, Latvia, Lebanon, Lithuania, Macedonia, The Former Yugoslav Republic of, Malaysia, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom, United States
- 2018-03-08
Recruiting
- A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
- Crohn Disease
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Finland, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-02-26
Recruiting
- Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Crohn Disease
- Australia, Austria, Brazil, Bulgaria, Canada, China, Finland, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United States
- 2018-02-14
Recruiting
- A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
- Metastatic Melanoma
- Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, Sweden, United States
- 2018-02-13
Recruiting
- Levels of Triglycerides and HDL-C in ACS Patients
- Dyslipidemia Associated With Acute Coronary Syndrome
- Egypt
- 2018-02-06
Recruiting
- Taking regular breaks from sitting to improve blood glucose control and blood vessel health in type 1 diabetes
- Type 1 diabetes; Type 1 diabetes;Metabolic and Endocrine - Diabetes;Cardiovascular - Hypertension
- Australia
- 2018-01-30
Recruiting
- A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of Getagozumab in Healthy Volunteers
- Plumonary Arterial Hypertension
- Australia
- 2018-01-29
Recruiting
- Does Metformin improve vascular function in youth with Type 1 diabetes
- Type 1 diabetes;Obesity;Vascular health
- Australia
- 2011-02-08
Recruiting
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- Breast Cancer;Cholangiocarcinoma;Colorectal Cancer;Head and Neck Neoplasms;Lymphoma, Large-Cell, Anaplastic;Melanoma;Neuroendocrine Tumors;Non-Small Cell Lung Cancer;Ovarian Cancer;Pancreatic Cancer;Papillary Thyroid Cancer;Primary Brain Tumors;Renal Cell Carcinoma;Sarcomas;Salivary Gland Cancers;Adult Solid Tumor
- Australia, Belgium, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom, United States
- 2015-10-02